Aligos Therapeutics, Inc.ALGS
Price (close)
$5.51
Market cap
$34.4M
P/E
—
Revenue (TTM)
$3.7M
Net income
-$76.0M
Dividend yield
—
1-year total return
-41.1%
Net margin
-2031.1%
Revenue growth
19.4%
Debt / equity
—
What Aligos Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.2M | $3.6M | $2.2M |
| Net income | -$108.5M | -$128.3M | -$96.0M | -$87.7M | -$131.2M | -$24.2M |
| Free cash flow | -$76.3M | -$116.6M | -$80.3M | -$79.0M | -$80.9M | — |
More on ALGS.
- Aligos Therapeutics, Inc. summary
- Aligos Therapeutics, Inc. financial statements
- Aligos Therapeutics, Inc. key metrics
- Aligos Therapeutics, Inc. health scores and style box
- Aligos Therapeutics, Inc. earnings
- Aligos Therapeutics, Inc. dividends
- Aligos Therapeutics, Inc. valuation
- Aligos Therapeutics, Inc. ownership and insiders
- Aligos Therapeutics, Inc. peers
Figures from Aligos Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.